S002 Dermatology Review: Skin Cancer, Surgical, and Cosmetic
DESCRIPTION
Cosmetic portion: We compare strategies for a novel pain medication used before and after cosmetic procedures, evaluate lasers and other modalities for scars, explore CO2 laser treatment of deep perioral and periocular rhytids, and examine ultrasound for safety and complication management in aesthetic practice.
General dermatologic/oncologic/reconstructive portion: We discuss available genetic studies for cancer management, review surgical strategies for medically complex patients, identify updates to the NCCN guidelines, and identify optimal cases for dermal substitutes in post-Mohs patients.
LEARNING OBJECTIVES
Compare and analyze different strategies for a novel new pain medication to be used pre- and post-cosmetic procedures.
Evaluate and optimize the use of lasers for scars and deep facial rhytids. Examine the use of ultrasound in the aesthetic practice.
Discuss available genetic studies for cancer management. Define strategies in surgical management of medically complex patients. Identify updates to the NCCN guidelines. Identify uses for dermal substitutes.
SCHEDULE
9:00 AM
Introduction
Naomi Lawrence, MD, FAAD
9:05 AM
Build a non-opioid, multimodal pain plan for office surgery and cosmetic procedures, including where suzetrigine (Journavx) fits, topical pain control, vibration
Anne M. Chapas, MD, FAAD
9:20 AM
Build a non-opioid, multimodal pain plan for office surgery and cosmetic procedures, including where suzetrigine (Journavx) fits, topical pain control, vibration | Discussion
9:35 AM
Ultrasound in Aesthetic Injectables: Applications for Safety and Complication Management
Hooman Khorasani, MD, FAAD
9:50 AM
Multimodal treatment of scars
10:05 AM
Optimizing Co2 laser for perioral and periocular rhytids
Kimberly J. Butterwick, MD, FAAD
10:20 AM
Cosmetic Discussion
Naomi Lawrence, MD, FAAD, Kimberly J. Butterwick, MD, FAAD, Hooman Khorasani, MD, FAAD
10:30 AM
Use of dermal substitutes in dermatologic surgery (ie. Integra, BTM)
Tara S. Jennings, MD
10:45 AM
Updates of NCCN guidelines
Kathryn Shahwan, MD, FAAD
11:00 AM
Surgical management of medically complex patients
Pooja Rambhia, MD, FAAD
11:15 AM
Genetic studies useful in CA management
Bryan T. Carroll, MD, PhD, FAAD
11:30 AM
Dermatologic Surgery Discussion
Naomi Lawrence, MD, FAAD, Bryan T. Carroll, MD, PhD, FAAD, Tara S. Jennings, MD, Pooja Rambhia, MD, FAAD, Kathryn Shahwan, MD, FAAD
DIRECTOR
Naomi Lawrence, MD, FAAD
Cooper Hospital Rowan University
SPEAKERS
Kimberly J. Butterwick, MD, FAAD
Bryan T. Carroll, MD, PhD, FAAD
Anne M. Chapas, MD, FAAD
Tara S. Jennings, MD
Pooja Rambhia, MD, FAAD
Cooper University Health care
Kathryn Shahwan, MD, FAAD
DISCLOSURES
Kimberly J. Butterwick, MD, FAAD
Allergan, Inc. – Advisory Board(Honoraria), Investigator(Grants/Research Funding); Evolus, Inc. – Advisory Board(Honoraria); Galderma – Advisory Board(Honoraria); Merz Pharmaceuticals, LLC – Advisory Board(Honoraria); Neutrogena Corporation – Advisory Board(Honoraria); Rapalogix Health – Stockholder Private Company(Stock); Revance Therapeutics, Inc. – Advisory Board(Honoraria);
Bryan T. Carroll, MD, PhD, FAAD
No financial relationships exist with ineligible companies.
Anne M. Chapas, MD, FAAD
Allergan, Inc – Speaker/Faculty Education(Honoraria); Cutera – Advisory Board(Fees); Cytrellis Biosystems, Inc – Speaker(Honoraria); Evolus, Inc. – Speaker(Honoraria); Galderma – Advisory Board(Fees); InMode MD Ltd – Investigator(Grants/Research Funding); Lumenis – Investigator(Grants/Research Funding); lutronic – Speaker(Honoraria); Revance – Investigator(Grants/Research Funding); reveance – Investigator(Grants/Research Funding); Rion Aesthetics – Investigator(Grants/Research Funding); sofwave – Speaker(Honoraria); Solta Medical – Speaker(Honoraria); Syneron Candela – Advisory Board(Honoraria);
Tara S. Jennings, MD
No financial relationships exist with ineligible companies.
Naomi Lawrence, MD, FAAD
No financial relationships exist with ineligible companies.
Pooja Rambhia, MD, FAAD
No financial relationships exist with ineligible companies.
Kathryn Shahwan, MD, FAAD
Highlight Therapeutics – Advisory Board(Honoraria); Sun Pharmaceutical – Advisory Board(Honoraria);